What question did this study set out to answer?

To evaluate the prognostic significance of marrow complete remission in patients with myelodysplastic syndrome undergoing hypomethylating agent therapy.

December 8, 2025Blood

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

View Full Paper

Ask AI

Bookmark

Authors

OBOndřej BláhaYale Cancer Center MSMikkael A. SekeresUniversity of Miami HCHetty E. CarrawayCleveland Clinic

Discussion

Member takes

Implication

Analysis reveals hypomethylating agent therapy affects overall survival in myelodysplastic syndrome patients post-allogenic stem cell transplantation, indicating new therapeutic guidelines may be more

Key Points

To evaluate the prognostic significance of marrow complete remission in patients with myelodysplastic syndrome undergoing hypomethylating agent therapy.
Included higher risk MDS patients treated with hypomethylating agents from the icMDS VALIDATE dataset
Assessed association of marrow complete remission with overall survival
Used Kaplan-Meier method for survival analysis and log-rank test for comparisons
1049 patients included; 17% achieved complete remission, 33% marrow complete remission
Median overall survival was superior for complete remission at 25 months compared to 16 months for marrow complete remission
IWG 2023 reclassification showed improved survival outcomes for patients who achieved composite complete remission compared to those without

Cite This Study

Bláha et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85b https://doi.org/10.1182/blood-2025-3865

View Full Paper

Ask AI

Bookmark

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider